Adar Poonawalla sells entire Panacea Biotec stake worth Rs 118 crore Ruchika Sharma19 May 2021 1:22 PM ISTNew Delhi: Serum Institute of India CEO Adar Poonawalla on Monday offloaded his entire stake in Panacea Biotec amounting to 5.15 per cent shareholding...
Panacea Biotec, RDIF to produce 100 million doses of Sputnik V per year in India Ruchika Sharma6 April 2021 11:57 AM ISTThe price of Sputnik V is less than $10 per shot, making it affordable around the world.
Panacea Biotec intimates of fire incident at Baddi plant Ruchika Sharma31 Dec 2020 12:02 PM ISTNew Delhi: Drug firm Panacea Biotec on Wednesday said a minor fire broke out at its manufacturing facility at Baddi, in Himachal Pradesh resulting in...
Panacea Biotec eyes to ramp up vaccine, pharma verticals to steer long-term growth Ruchika Sharma7 Dec 2020 1:00 PM ISTNew Delhi: Panacea Biotec is looking to scale up its existing product portfolio, develop new medications and foray into new markets as part of its...
Panacea Biotec Baddi plant fails to establish laboratory controls, gets USFDA warning letter Farhat Nasim5 Oct 2020 3:11 PM IST"Your firm failed to establish laboratory controls that include scientifically sound and appropriate specifications, standards, sampling plans, and...
Panacea Biotec Baddi unit gets USFDA warning letter Ruchika Sharma1 Oct 2020 12:00 PM ISTNew Delhi: Drug firm Panacea Biotec on Wednesday said it has received a warning letter from the US health regulator for its pharmaceutical formulation...
Panacea Biotec DengiAll vaccine completes phase 1/2 study Ruchika Sharma26 Sept 2020 11:45 AM ISTDengiAll is a single-dose live-attenuated tetravalent vaccine.
Panacea Biotec ends COVID Vaccine MoU entered with Refana Ruchika Sharma25 Aug 2020 2:39 PM ISTPanacea Biotec informed that the termination is due to delays in project timelines and difficulty in moving ahead with the joint venture.
COVID-19: Seven Indian Pharma firms in relay to develop vaccine Ruchika Sharma20 July 2020 12:34 PM ISTBharat Biotech, Serum Institute, Zydus Cadila, Panacea Biotec, Indian Immunologicals, Mynvax and Biological E are among the domestic pharma firms...
COVID-19: Panacea Biotec sees production of 1 billion doses of vaccine candidate in 2022 Ruchika Sharma10 July 2020 3:21 PM ISTThe company has production targets of 500 million doses for 2021 and one billion doses in 2022 for its COVID-19 vaccine candidate, Panacea said in an...
Panacea Biotec, Refana enter landmark collaboration for COVID-19 Vaccine Farhat Nasim10 Jun 2020 6:15 PM ISTCollaboration will enable global development, manufacturing and distribution of the Candidate COVID-19 vaccine.
Narayana Health launches first Pediatric Hospital in Mumbai to bolster its Western cluster supriya kashyap kashyap25 April 2017 9:38 AM ISTBangalore : Narayana Hrudayalaya Limited (NH), a leading healthcare services provider in India, has launched in-patient services at its SRCC...
